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Abstract Patientswithmoderate persistent asthma (n = 523; mean FEV177.4%) not fullycontrolledwith inhaled cor-
ticosteroids (ICS; 400^1000 mg/day) were randomized to receive either once-daily budesonide/formoterol (160/4.5 mg,
two inhalations); or twice-daily budesonide/formoterol (160/4.5 mg, one inhalation); or budesonide (400 mg) once-daily
for12 weeks.Once-daily dosing was administered in the evening and twice-daily dosing was administered in themorn-
ing and evening. All patients received twice-daily budesonide (200 mg) during a 2-week run-in.Comparedwith budeso-
nide alone, change inmeanmorningand eveningpeakexpiratory flowwasgreater inthe once-dailybudesonide/formo-
terol group (27 and171min1, respectively; Po0.001) and twice-daily budesonide/formoterol group (23 and 241min1,
respectively; Po0.001). Night awakenings, symptom-free days, reliever-use-free days and asthma-control days were
all improved during once-daily budesonide/formoterol therapy vs. budesonide (P0.05). Similar improvements were
also seen with twice-daily budesonide/formoterol (P0.05). The risk of a mild exacerbation was reduced after once-
and twice-dailybudesonide/formoterolvs. budesonide (38% and 35%, respectively;Po0.002).All treatmentswerewell
tolerated.Budesonide/formoterol, once- or twice-daily, in a single inhaler improved asthma symptoms and exacerba-
tions compared with budesonide. In the majority of patients with moderate persistent asthma requiring ICS and long-
acting b-agonists, once-daily formoterol/budesonideprovided sustained efficacyover 24 h, similar totwice-dailydosing.
r 2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1427, available online at http://www.sciencedirect.com
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The role of combined therapy with inhaled corticoster-
oids (ICS) andlong-actingb2-agonists in themanagement
of moderate-to-severe asthma is well established (1^3).
Until recently, combination therapy with ICS and long-
acting b2-agonists was administered via two inhalers,
and in addition, patients needed a third inhaler for relie-
vermedication.Thismultiple inhaler approach to asthma
treatment is potentially confusing for the patient and is
associatedwith reduced treatment compliance and poor
inhaler technique (4). In recent years, a concerted e¡ortReceived15 July 2002, accepted in revised form 29 July 2002
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E-mail: R.Buhl@3-med.klinik.uni-mainz.dehas been made to simplify asthma treatment. The ¢rst
step in simplifying asthma treatment was to combine
both controller treatments (ICS and inhaled long-acting
b2-agonist) in a single inhaler.Thenext step,when appro-
priate, is to reduce the dosing frequency to theminimum
necessary to maintain asthma control.
The e⁄cacy of budesonide and formoterol in a single
inhaler administered twice-daily has already been re-
ported (5). In that study, budesonide/formoterol 160/
4.5mg, two inhalations twice-daily quickly gained asthma
control and was at least as e¡ective as budesonide and
formoterol given via two separate inhalers in patients
with moderate-to-severe asthma (5). In a second single-
dose study (6), budesonide/formoterol 160/4.5mg was
shown to have a rapid onset of e¡ect with the majority
of patients (473%) achieving a15% increase in forced ex-
piratory volume in 1s (FEV1) after 1h. Another study in
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lighted the 24-h e⁄cacy of once-daily budesonide or for-
moterol given alone or in combination via two separate
inhalers (7).These factors support the once-daily admin-
istration of budesonide and formoterol in a combined
treatment regimen.
Here we present the ¢rst study to examine the e⁄-
cacy of budesonide/formoterol 160/4.5mg, two inhala-
tions administered once-daily.The aim of the study was
to compare the e⁄cacyof once-dailybudesonide/formo-
terol with that of once-daily budesonide (400mg) alone
and twice-daily budesonide/formoterol and to show that
a simple treatment regimen (i.e. one inhaler, once a day)
is e¡ective even in patients with moderate persistent
asthma.
METHODS
Patients
Adults (aged at least 18 years) with asthma (minimum
duration 6 months) were eligible for inclusion in this
study if they had been using any inhaled corticosteroid
(irrespective of the speci¢c drug) at a constantdaily dose
of 400^1000mg for at least 30 days before entry and still
had sub-optimal asthma control. At enrolment, patients
had baseline FEV1 of 60^90% of predicted normal and a
reversibility from baseline FEV1 of at least 12% at 15min
after inhalation of a short-acting b2-agonist. Patients
were excluded if in the 4weeksbefore the run-in period,
they required treatment with systemic corticosteroids
or had a respiratory tract infection.Other exclusion cri-
teria included any severe cardiovascular disorders, use of
b-blocker therapy or a history of heavy smoking (10
pack-years). All patients gave their written, informed
consent prior to commencing the study.
Study design
Thiswas a randomized, double-blind, double-dummy, ac-
tive-controlled study with a parallel-group design con-
ducted at 56 centres in nine countries (Argentina,
Belgium, Czech Republic, Germany, Mexico, Russia,
Spain, The Netherlands and the United Kingdom). The
study protocol was approved by local ethics committees
and the study was conducted in accordancewith theDe-
claration ofHelsinki andgood clinical practice guidelines.
At the initial visit, patients underwent a physical ex-
amination and a complete medical and respiratory his-
tory was taken. Patients then entered a 2-week run-in
period during which they received budesonideTurbuha-
lers (200mg) twice daily. At the endof therun-in period,
patients were randomized to receive either: once-daily
budesonide/formoterol (160/4.5mg, two inhalations); or
twice-daily budesonide/formoterol (160/4.5mg, one inha-
lation); or once-daily budesonide (400mg) for 12 weeks.When asthma medication was administered once daily,
the doses were taken in the evening. All patients re-
ceived an equivalent daily dose of budesonide; apparent
di¡erences in dose levels are due to the doses being ex-
pressed as delivereddose for budesonide/formoterol and
as metered dose for budesonide alone. To ensure treat-
ment blinding, patients inhaled once from a numbered
inhaler in the morning upon rising and then from three
consecutively numbered inhalers in the evening just be-
fore going to bed, with the corresponding placebo inha-
lers being identical in appearance to those containing
active medication. Patients returned for clinic visits 4, 8
and 12 weeks after randomization. All clinic visits took
place between 07.00 and10.00h.
No concomitant asthma medicationwas allowed dur-
ing the study, with the exception of the inhaled short-
acting b2-agonistmedication terbutaline sulphate (Brica-
nyls Turbuhaler 0.5mg/dose), which was to be taken as
needed. The need for oral corticosteroids or any other
change in asthma therapy led to withdrawal of the pa-
tient from the study.
E⁄cacy assessments
Peak expiratory £ow (PEF) measurements and severity
of asthma symptoms were recorded each morning and
evening by the patients on daily diary cards for the dura-
tion of the study. Morning and evening PEF were mea-
sured, with the patient standing, using a Mini-Wrights
peak £ow meter (Clement Clark, Harlow, UK) before
the intake of study medication. On each occasion, the
highest value of three readings was recorded. Daytime
and night-time asthma symptomswere graded on a scale
of 0^3 (0=no symptoms; l=mild; 2=moderate; 3=severe)
and the total daily asthma symptom score (on a scale of
0^6) was the sum of the daytime and night-time symp-
tom scores. Patients also recorded any night-time awa-
kenings due to asthma and use of reliever
bronchodilator medication during the day and night.
Thepercentages of symptom-free days, reliever-use-free
days, asthma-control days and asthma-control weeks
were calculated. A symptom-free day was de¢ned as a
day andnightwith a total asthma symptom score of zero.
A reliever-free day was a 24-h period with no reliever
medication use. An asthma-control day was de¢ned as a
day and night with no asthma symptoms, no reliever
medication use andno night-time awakening due to asth-
ma. Asthma-control weeks were study weeks during
which patients experienced no symptoms, had no awa-
kenings due to their asthma and used minimal reliever
medication (4 inhalations/week on a maximum of 2
days).
Amild exacerbationwas de¢ned as 2 consecutivemild
exacerbation days (for the same criterion), the latter
being de¢ned as night-time awakening due to asthma;
ONCE-DAILYBUDESONIDE/FORMOTEROL 32520%decrease in PEF frombaseline; or4 inhalations of
relievermedication over a 24-h period. Severe exacerba-
tions were de¢ned as asthma deterioration requiring
oral corticosteroid treatment; or a 30% decrease in
PEF from baseline on 2 consecutive days; or discontinua-
tion due toworsening of asthma.
Lung function tests were performed at all clinic visits.
Spirometry was performed according to European Re-
spiratory Society recommendations (8). Patients were
requested not to take their morning dose of studymed-
ication before attending the clinic and to refrain from
taking any reliever medication during the 6h prior to
lung function testing at the clinic. After a15min rest, pa-
tients performed at least three forced expiratory man-
oeuvres. The highest of three FEV1 values obtained was
recorded at each visit.
Safety assessments
Safety was assessed by recording adverse events at all
clinic visits. Adverse events were either reported spon-
taneouslyby thepatientor in response to standard ques-
tions asked by the investigator. All adverse events were
classi¢ed in terms of intensity (mild,moderate or severe)
and causal relationship to study medication (probable,
possible, unlikely). Deterioration of asthma and asthma-
related signs and symptoms were only recorded as ad-
verse events if they were serious adverse events or re-
sulted in discontinuation of studymedication.
Statistical analysis
Theprimary e⁄cacy variablewas the change inmorning
PEF from baseline to the end of the 12-week treatment
period.
All e⁄cacy variables were analysed on an intent-to-
treat basis and all randomized patients with data were
included in the analysis. For PEF measurements and
other diary-card variables, baseline values were de¢ned
as the average over the last10 days of the run-in period,
and the treatment valuewas the average over the entire
treatment period.Comparisons of the treatments were
performed using analysis of variance (ANOVA) with
treatment and country as factors; average baseline va-
lues were used as covariates.The FEV1value obtained at
randomizationwas considered as the baseline, and base-
line vs. treatmentvalueswere analysed in amultiplicative
ANOVAmodel.The time to ¢rst mild exacerbation was
analysedwith a log-rank test and further describedwith
a Cox’s proportional hazardsmodel. For asthma control
weeks’ data could be viewed as a binary correlated ob-
servation series, and this was analysed in a generalized
estimation equation (GEE) with a logistic link function,
an exchangeable dependency model and patient as clus-
ter.The factors were treatment and asthma control dur-ing the last weekof run-in.The estimated log-odds were
used in the comparisons giving odds ratios which were
interpreted as risk factors. A signi¢cance level of 5%
was assumed.
RESULTS
Study populations
Atotal of 549 patientswere enrolled into the study.Dur-
ing the 2-week run-in period, all patients receivedbude-
sonide 200mg bid, a dose chosen because of the very £at
nature of the dose^response curve of budesonide. Pa-
tients who deteriorated during the run-in period were
not entered into the study. At visit 2, 523 patients (199
men, 324 women) were randomized to treatment with
once-daily budesonide/formoterol (n = 176), twice-daily
budesonide/formoterol (n = 176), or once-daily budeso-
nide (n = 171). All randomized patients were included in
the e⁄cacy and safety analyses. At baseline, the three
treatmentgroupswerewellmatchedwith regard to lung
function, symptoms, reliever medication use and pre-
study ICS dose (Table1).
Four hundredandeightypatients completed the study.
The three treatment groups were comparable with re-
spect to numbers and reasons for patients discontinuing
treatment. A total of 43 patients (14 in the once-daily bu-
desonide/formoterol group,15 in the twice-daily budeso-
nide/formoterol group and 14 in the once-daily
budesonide group) discontinued the study. The number
of patients discontinuing as a result of asthma deteriora-
tionwas similar in the once-daily budesonide/formoterol
group (n = 5), twice-daily budesonide/formoterol group
(n = 4), and once-dailybudesonide group (n = 5).Nine pa-
tients in the once-daily budesonide/formoterol group,11
patients in the twice-daily budesonide/formoterol group
and nine patients in the once-daily budesonide group did
not complete the study for other reasons.
Lung function
Compared with the run-in period, morning PEF re-
mained stable in the group of patients switched from
twice-daily to once-daily budesonide [change (D);
0.951min1].Therewas, however, a signi¢cant increase
in morning PEF in both the once-daily budesonide/for-
moterol group (D; 27.41min1) and the twice-daily bude-
sonide/formoterol group (D; 22.81min^1) comparedwith
the budesonide-alone group (Po0.001).These treatment
bene¢ts were apparent on the ¢rst day after randomiza-
tion andweremaintained throughout the12-week treat-
ment period (Fig. 1). The di¡erence between the once-
and twice-daily budesonide/formoterol groups was not
signi¢cant.The percentage of patients in each treatment
group with a clinically relevant increase in morning PEF
(415 lmin1) from run-in was 64% in the once-daily
TABLE 1. Meanbaseline characteristics
Patients’characteristics Budesonide/
formoterol qd
(n = 176)
Budesonide/
formoterolbid
(n = 176)
Budesonide onlyqd
(n = 171)
Age (years) [range] 42.7 [18^77] 44.8 [18^74] 45.5 [18^78]
Men/women 67/109 64/112 68/103
Asthma duration (years) 12.7 [0^62] 12.3 [1^63] 14.5 [0^62]
Nonsmoker/current smoker/past smoker 140/10/26 124/16/36 127/14/30
Inhaled corticosteroid dose ( mg/day) 592 626 612
FEV1 (1) [range]
a,b 2.32 [1.1^4.5] 2.25 [0.8^5.0] 2.28 [1.1^4.5]
FEV1 (% predicted) [range]
b 77.1 [44^126] 77.6 [43^111] 77.6 [33^132]
Reversibility (%) [range]c 21.5 [12^99] 21.2 [11^77] 22.6 [12^78]
Morning PEF (1min1) [range]d 350 [143^728] 351 [167^707] 344 [142^659]
Evening PEF (1min1) [range]d 359 [154^724] 362 [174^773] 354 [146^674]
Total symptom score (0^6 scale)d 1.0 1.1 1.1
Nightswith awakenings (%) [range]d 14.5 [0^100] 10.0 [0^100] 15.5 [0^100]
Symptom-free days (%)[range]d 44.3 [0^100] 43.5 [0^100] 39.4 [0^100]
Asthma-control days (%)[range]d 37.4 [0^100] 38.6 [0^100] 34.0 [0^100]
Use of reliever medication (inhalations/
day) [range]d
1.1 [0^6] 1.1 [0^8] 1.2 [0^8]
aGeometricmean.
bMeasurements taken atthe end of run-in period (i.e. at randomization).
cMeasurements taken atenrolment.
dAverage values over the last10 days of the run-inperiod.
qd: once daily; bid: twice daily;FEV1: forced expiratory volume in1s;PEF: peakexpiratory £ow.
FIG. 1. Daily change in mean morning peak expiratory £ow
(PEF) from run-in with once-daily budesonide/formotero1(160/
4.5 mg, two inhalations), twice-daily budesonide/formoterol
(160/4.5 mg, one inhalation) and once-daily budesonide (400 mg)
alone.Allpatientsreceivedbudesonide 200 mg twicedailyduring
run-in.
326 RESPIRATORYMEDICINEbudesonide/formoterol group, 55% in the twice-daily bu-
desonide/formoterol group and 27% in the budesonide-
alone group.
Evening PEF was greater in the once- and twice-daily
budesonide/formoterol groups comparedwith the group
treated with budesonide alone, and there was a mean
treatmentdi¡erence of16.6 and 23.61min1for the once-and twice-daily budesonide/formoterol groups, respec-
tively, vs. budesonide (Po0.001; Table 2). Moreover, the
percentage of patients with a clinically relevant increase
in evening PEF (4151min1) fromrun-inwas signi¢cantly
greater after budesonide/formoterol administration,
once- and twice-daily, comparedwith budesonide alone.
Mean FEV1was also signi¢cantly greater in the once-
daily budesonide/formoterol group (2.321) and twice-
daily budesonide/formotero1 group (2.37 l) than in the
budesonide group (2.22 l; Po0.001). The di¡erence be-
tween the once- and twice-daily budesonide/formoterol
groups was not statistically signi¢cant.
Symptomcontrol and use of reliever
medication
As expected, once- and twice-daily budesonide/formo-
terol treatmentresulted in consistentlygreater improve-
ments in symptommeasures comparedwith budesonide
alone in terms of total asthma symptom score, night-
time awakenings, symptom-free days and asthma-con-
trol days. In addition, total daily reliever use and relie-
ver-use-free days were signi¢cantly improved in the
once- and twice-daily budesonide/formoterol groups
compared with the budesonide-alone group (Table 2).
There were no signi¢cant di¡erences between once-
and twice-daily budesonide/formoterol with respect to
TABLE 2. E¡ectof12-weeks’treatmentwith once-dailybudesonide 400 mg, once-dailybudesonide/formoterol160/4.5 mg, two
inhalations or twice-daily budesonide/formoterol160/4.5 mg, one inhalation onpatient-reported secondary variables
E⁄cacy variable Treatment Treatment
mean
Meantreatment
di¡erence
95% con¢dence
limit
D in evening PEF (1min1) Bud onlyqd 4.8
Bud/formqd 11.8 16.6*** 9.6, 23.6
Bud/formbid 18.8 23.6*** 16.6, 30.6
Total asthma symptom score (0^6 scale) Bud onlyqd 0.90
Bud/formqd 0.76 0.14* 0.27,0.00
Bud/formbid 0.78 0.12 0.25,0.01
Symptom-free days (%) Bud onlyqd 51.3
Bud/formqd 58.6 7.3* 1.5,13.1
Bud/formbid 58.2 6.9* 1.1,12.7
Asthma-control days (%) Bud onlyqd 47.6
Bud/formqd 55.2 7.6* 1.7,13.5
Bud/formbid 53.5 5.9* 0.0,11.7
Nightswith awakenings (%) Bud onlyqd 14.1
Bud/formqd 9.9 4.2** 7.3,1.1
Bud/formbid 12.1 2.1 5.3,1.0
Reliever-use-free days (%) Bud onlyqd 59.7
Bud/formqd 68.6 8.9** 3.2,14.7
Bud/formbid 70.7 11.0*** 5.3,16.8
D in reliefmedicationuse (inhalations/day) Bud onlyqd 0.10
Bud/formqd 0.37 0.27** 0.45,0.09
Bud/formbid 0.45 0.35*** 0.56,0.17
Bud: budesonide.Bud/form: budesonide/formoterol. qd: once daily. bid: twice daily.
D: meanchange fromrun-in.PEF: peakexpiratory £ow.
*Po0.05,**Po0.01,***Po0.001vs. budesonide alone;
FIG. 2. Percentage of patientswith an asthma-control day (no
night-time awakening, no asthma symptoms and no relief medi-
cation use) during treatment with once-daily budesonide/for-
moterol (160/4.5 mg, two inhalations), twice-daily budesonide/
formoterol (160/4.5 mg, oneinhalation) oronce-dailybudesonide
(400 mg) alone. All patients received budesonide 200 twice daily
duringrun-in.
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an asthma control day during the 12-week treatment
period is shown in Fig. 2. Treatment with once- and
twice-daily budesonide/formoterol increased the num-
ber of asthma-control days by 7.6% and 5.9%, respec-
tively, giving an estimated extra 28 and 21 days year1
free of asthma symptoms and the need for relievermed-
ication. In all three groups, the proportion of patients
with an asthma-control week increased progressively
during treatment.The percentage of patients with asth-
ma control in the once- and twice-daily budesonide/for-
moterol groups and the budesonide-alone group during
the last week of run-in was 17%, 19% and 17%, respec-
tively.During the ¢rst 4weeks of treatment, thepercen-
tage of patients with an asthma-control week in the
once- and twice-daily budesonide/formoterol treatment
groups and the budesonide-alone group increased to
3l%, 33%, and 23%, respectively, with further increases
to 42%, 41% and 29%, respectively, during the last 4
weeks of treatment. Over the whole study period,
comparedwith the budesonide-alone group, the average
chance of achieving an asthma-control week during
the study was 99% higher [odds ratio 1.99; 95%
con¢dence limit (CL) 1.39^2.84; Po0.001) in the
once-daily budesonide/formoterol group and 80% higher
(odds ratio 1.80; 95% CL 1.25^2.60; Po0.001) in thetwice-daily budesonide/formoterol group. Throughout
the study, no di¡erence in symptom control asmeasured
by asthma-control days was observedbetween once- or
328 RESPIRATORYMEDICINEtwice-daily dosing with budesonide/formoterol (Table 2;
Fig. 2).
Exacerbations of asthma
The Kaplan-Meier survival curves for time to ¢rst mild
exacerbation for each treatment group are shown in Fig.
3. Two or more consecutive nights with disturbed sleep
due to asthma was the most common reason (63% of all
cases) de¢ning a mild asthma exacerbation. Patients re-
mainedexacerbation-free for amedian time of 80 days in
the once-daily budesonide/formoterol group, 78 days in
the twice-dailybudesonide/formoterolgroup and 42days
in the budesonide-alone group (Po0.001 vs. budesonide
alone; log-rank test). Cox’s proportional hazards model
revealed that in comparison to the budesonide-alone
group, the relative risk of having a mild exacerbation
was 38% lower in the once-daily budesonide/formoterol
group (hazard ratio 0.62; 95% CL 0.46^0.84; Po0.001)
and 35% lower in the twice-daily budesonide/formoterol
group (hazard ratio 0.65; 95% CL 0.49^0.88;Po0.002).FIG 3. Kaplan^Meier survival curves of the time to ¢rst mild
asthmaexacerbationduring12weeks’treatmentwithonce-daily
budesonide/formoterol (160/4.5 mg, twoinhalations), twice-daily
budesonide/formoterol (160/4.5 mg, oneinhalation) oronce-daily
budesonide (400 mg) alone.
TABLE 3. Most frequentlyreported (3%) adverse events exp
Adverse event Budesonide/formoterol qd
(n= 176)
Respiratory infection 12 (6.8%)
Bronchitis 9 (5.1%)
Viral infection 6 (3.4%)
Aggravated asthma 6 (3.4%)
Rhinitis 6 (3.4%)
Pharyngitis 7 (4.0%)The incidence of severe exacerbations was compar-
able across the treatment groups, with a pattern similar
to that observed formild exacerbations. A total of 8% of
patients in the once-daily budesonide/formoterol group
and 9% of patients in the twice-daily budesonide/formo-
terol group experienced a severe exacerbation com-
pared with 11% of patients in the budesonide-alone
group.Overall, the incidences of mild and severe asthma
exacerbations were numerically lower in the once-daily
budesonide/formoterol group (42% and 8%, respectively)
than those observed in the twice-daily budesonide/for-
moterol group (45% and 9%, respectively) with no signif-
icant di¡erence between the groups.
Safety
Budesonide monotherapy and once- and twice-daily bu-
desonide/formoterol were well tolerated. Seventy-one
patients (40%) in the once-daily budesonide/formoterol
group, 60 patients (34%) in the twice-daily budesonide/
formoterol group, and 78 (46%) in the budesonide-alone
group experienced at least one adverse event during the
study. The number, nature and intensity of the adverse
events were similar across all three treatment groups.
The most frequently reported adverse event was re-
spiratory infection as shown inTable 3. There were ¢ve
serious adverse events: one in the once-daily budeso-
nide/formoterol group and two each in the other two
treatment groups.They included one death due to cardi-
ac arrest and four other serious adverse events (ectopic
pregnancy, aggravated asthma, tachycardia and at-
tempted suicide). None of these events was considered
related to the studymedication.
DISCUSSION
This is the ¢rst study to demonstrate that once-daily bu-
desonide/formoterol in a single inhaler (160/4.5mg, two
inhalations) provides sustained improvement in asthma
control in patients with moderate persistent asthma
who were not previously fully controlled on ICS alone.
Compared with once-daily budesonide, in terms of lungeriencedbypatients in anyofthe three treatmentgroups
Budesonide/formoterolbid
(n = 176)
Budesonide onlyqd
(n= 171)
14 (8.2%) 15 (8.5%)
4 (2.3%) 10 (5.7%)
5 (2.9%) 9 (5.1%)
6 (3.5%) 7 (4.0%)
7 (4.1%) 6 (3.4%)
3 (1.8%) 3 (1.7%)
ONCE-DAILYBUDESONIDE/FORMOTEROL 329function and asthma symptoms, once-daily budesonide/
formoterol showed improved e⁄cacy, sustained
throughout the 24-h dosing interval. In addition, the im-
provements in asthma symptoms and asthma exacerba-
tion control shown with once-daily budesonide/
formoterol were comparable with those seen with
twice-daily budesonide/formoterol.
The sustained 24-h e¡ect of once-daily budesonide/
formoterol, as shown in our study, was not unexpected
given that residual 24-h activity after a standard dose of
formoterol (9mg) has been reported previously (9).
Other studies using a standard dose of formoterol (4.5
or 9mg) have demonstrated similar bronchodilatory ef-
fects to salmeterol (50mg) for up to 12h (10,11). A high
dose of formoterol (equivalent to 18mg delivered dose)
has been reported to protect against signi¢cant falls in
FEV1due to allergen provocation for up to 32h (12).The
duration of action of formoterol is, therefore, in excess
of 12h at the lowest recommended dose and potentially
greater than 24h at the upper recommended daily dose
(equivalent to18mg delivered dose).
The dosing frequency of asthma treatment, particu-
larly for an ICS such as budesonide, has been evaluated
extensively in order to determine the optimal frequency
formaximume⁄cacy and safety.Early studies conducted
with budesonide aerosol in patients with severe asthma
in relapse showed that asthma control wasmore rapidly
re-established with more frequent dosing of ICS (e.g. up
to four-times daily) (13,14). Toogood and colleagues (13)
also showed that increasing the dosing frequency above
twice-daily had no discernible bene¢t in patients with
stable asthma. It has long been recognized that adher-
ence to prescribed chronic therapy is reduced with in-
creasing complexity and frequency of treatment
(4,15,16). Thus, when appropriate, once-daily administra-
tion of prescribed medication should be the treatment
goal.Once-daily dosing of ICS has been assessed in mild-
to-moderate asthma (15,17). In these studies, once-daily
budesonide was found to be as e¡ective as twice-daily
budesonide (17) and twice-daily £uticasone (15). In this
study, we have demonstrated that budesonide adminis-
tered once-daily maintains asthma control in many pa-
tients who were previously well controlled with twice-
daily dosing and this ¢nding supports that of previous
studies (17,18).
Asthma is widely recognized as a disease with large
circadian variations both in lung function and symptoms,
frequently characterizedby nocturnal and earlymorning
worsening (19). Thus, the view that chronotherapy (i.e.
the timing of dosing) is important to asthma treatment
has received increased emphasis. Because airway in£am-
mation is worse in the evening and early morning, it is
logical to maximize the concentration of ICS in the air-
ways at these times (20) and this can be achieved by ad-
ministering theprescribedmedication during the second
half of the day. In studies comparing once-daily morningand once-daily evening budesonide administration, no
signi¢cant di¡erences in e⁄cacy have been observed;
however, trends towards superior e⁄cacy were ob-
served with evening dosing (21,22). In another study of
nocturnal asthma, once-daily prednisone (50mg) admi-
nistered at15.00h was more e¡ective in improving FEV1
at 04.00h than dosing at either 08.00h or 20.00h (23).
Thus, several lines of evidence support the concept that
the timing of the dose is important, and that a late after-
noon or early evening dose tends to be superior to
morning dosing. For these reasons, in the current study
onlyevening administration of once-daily therapy was in-
vestigated.
Previous studies with once-daily budesonide (400^
800mg administered in the evening) in moderate persis-
tent asthma have shown similar e⁄cacy to equivalent or
higherdailydoses of budesonide administered twice daily
(22,24), or equivalent daily doses of twice-daily £utica-
sone propionate (15). Indeed, in the current study, morn-
ing PEF remained stable and the number of asthma-
control days improved when patients switched from
twice-daily budesonide (run-in) to a once-daily regimen
(Figs.1and 2).Despite ICS treatment,manypatientswith
moderate persistent asthma still experience nocturnal
symptoms, earlymorning dyspnoea and diminished qual-
ity of life.Thus, for these patients it would bemore logi-
cal to have a long-acting bronchodilator, such as
formoterol, administered in the evening rather than in
the morning, or alternatively a single higher dose in the
evening rather than lower doses in themorning and eve-
ning. In our study population, two out of every three pa-
tients in the budesonide group who experienced a mild
exacerbation reported consecutive nights with noctur-
nal awakenings and this ¢nding further supports the
concept of a need for once-daily evening dosing.
Once-daily evening dosing with budesonide/formoter-
olmet all the key goals of asthma management, in parti-
cular reducing daytime and nocturnal symptoms,
improving morning and evening PEF, reducing the need
for reliever medication and decreasing the incidence of
asthma exacerbations vs. budesonide alone. Once-daily
evening dosing with budesonide/formoterol provides
equivalent e⁄cacy to twice-daily budesonide/formoter-
ol on asthma-control variables such as asthma-control
days, asthma-control weeks and risk of asthma exacer-
bations. This ¢nding further suggests that a single high
dose of budesonide/formoterol in the evening could be a
logical andrealistic treatmentoption inmoderatepersis-
tent asthma.
The acceptance of once-daily budesonide/formoterol
in a single inhaler is likely to be higher than for once-daily
budesonide alone given the greater e⁄cacy andmore ra-
pid symptom relief provided by formoterolFa long-act-
ing bronchodilator with a rapid onset of action (10,11).
Consequently, the once-daily budesonide/formoterol
single inhaler delivers the additional e⁄cacy patients
330 RESPIRATORYMEDICINErequire whilst encouraging optimal adherence to long-
term inhaled corticosteroid therapy with the simplest
of dosing options (i.e. one inhaler once daily) (25).
In conclusion, once-daily budesonide/formoterol in a
single inhaler was as e¡ective as twice-daily budeso-
nide/formoterol in improving asthma control, and both
regimens weremore e¡ective than budesonide alone. In
the majority of patients with moderate persistent asth-
ma requiring therapy with ICS and long-acting b2-ago-
nists, once-daily budesonide/formoterol provided
sustainede⁄cacyover 24h, similar to twice-daily dosing.
This study indicates that it is possible to reduce the dos-
ing frequency with budesonide/formoterol to once daily
in patients with moderate persistent asthma, without
loss of asthma control. The simplicity of this treatment
regimen (i.e. one inhaler, once a day)mayhelp to improve
patient adherence to treatment.
Acknowledgements
This study was supported by AstraZeneca, Lund, Swe-
den.
REFERENCES
1. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol
versus higher-dose corticosteroid in asthma patients with
symptoms on existing inhaled corticosteroid. Lancet 1994; 344:
219–224.
2. Woolcock AJ. The combined use of inhaled salmeterol and inhaled
corticosteroids. Eur Respir Rev 1995; 5: 142–145.
3. Pauwels RA, Lofdahl C-G, Postma DS, et al. Effect of inhaled
formoterol and budesonide on exacerbations of asthma. N Engl J
Med 1997; 337: 1405–1411.
4. Horn CR, Clark TJH, Cochrane GM. Compliance with inhaled
therapy and morbidity from asthma. Respir Med 1990; 84: 67–70.
5. Zetterstro¨m O, Buhl R, Mellem H, et al. Improved asthma control
with budesonide/formoterol in a single inhaler, compared with
budesonide alone. Eur Respir J 2001; 95: 1–7.
6. Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lo¨tvall J. Onset
of bronchodilation of budesonide/formoterol vs salmeterol/
fluticasone in single inhalers. Pulm Pharmacol Ther 2001; 14: 29–34.
7. Aziz I, Wilson AM, Lipworth BJ. Effects of once-daily formoterol
and budesonide given alone or in combination on surrogate
inflammatory markers in asthmatic adults. Chest 2000; 118: 1049–
1058.
8. Quanjer PhH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R,
Yernault J-C. Lung volumes and forced ventilatory flows. Report
Working Party Standardization of Lung Function Tests, European
Community for Steel and Coal. Official Statement of the European
Respiratory Society. Eur Respir J 1993; 6: 5–40.9. Rabe KF, Jo¨rres R, Nowak D, Behr N, Magnussen H. Comparison
of the effects of salmeterol and formoterol on airway tone and
responsiveness over 24 hours in bronchial asthma. Am Rev Respir
Dis 1993; 147: 1436–1441.
10. Ringdal N, Derom E, Wahlin-Boll E, Pauwels R. Onset and
duration of action of single doses of formoterol inhaled via
Turbuhalers. Respir Med 1998; 92: 1017–l021.
11. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lo¨tvall J.
Inhaled dry-powder formoterol and salmeterol in asthmatic
patients: onset of action, duration of effect and potency. Eur Re-
spir J 1997; 10: 2484–2489.
12. Brusasco V, Crimi E, Gherson G, Nardelle R, Oldani V, Fabbri L.
Protective effect of formoterol against the late-phase asthmatic
response to allergen. Eur Respir J 1997; 10: 474S.
13. Toogood JH, Baskerville JC, Jennings B, Lefcoe NM, Johansson SA.
Influence of dosing frequency and schedule on the response of
chronic asthmatics to the aerosol steroid, budesonide. J AllergyClin
Immunol 1982; 70: 288–298.
14. Malo JL, Cartier A, Merland N, et al. Four-times-a-day dosing
frequency is better than a twice-a-day regimen in subjects
requiring a high-dose inhaled steroid, budesonide, to
control moderate to severe asthma. Am Rev Respir Dis 1989; 140:
624–628.
15. Venables TL, Addlestone MB, Smithers AJ, et al. A comparison of
the efficacy and patient acceptability of once daily budesonide via
Turbuhaler and twice daily fluticasone propionate via a disc-inhaler
at an equal dose of 400mg in adult asthmatics, Br JClin Res 1996; 7:
15–32.
16. Simons FE. Inhaled glucocorticoids in children: a favourable
therapeutic index. Can Respir J 1999; 6: 175–178.
17. McFadden ER, Casale TB, Edwards TB, et al. Administration of
budesonide once daily by means of Turbuhalers to subjects with
stable asthma. J Allergy Clin Immunol 1999; 104: 46–52.
18. Chisholm L, Dekker FW, Knuistingh Neven A, Petri H. Once-daily
budesonide in mild asthma. Respir Med 1998; 92: 421–425.
19. Silkoff PE, Martin RJ. Pathophysiology of nocturnal asthma, Ann Al-
lergy Asthma Immunol 1998; 81: 878–883.
20. Martin RJ. Small airway and alveolar tissue changes in nocturnal
asthma. Am J Respir Crit Cure Med 1998; 157: S188–S190.
21. Jones AH, Langdon CG, Lee P, etal. PDI. Pulmicorts Turbuhalers
once daily as initial prophylactic therapy for asthma. Respir Med
1994; 88: 293–299.
22. Campbell LM, Gunn SD, Sweeney D, et al.Once daily budesonide:
effective control of moderately severe asthma with 800mg once
daily inhaled via Turbuhaler when compared with 400mg twice
daily. Eur J Clin Res 1995; 7: 1–14.
23. Beam WR, Weiner DE, Martin RJ. Timing of prednisone and
alterations of airways inflammation in nocturnal asthma. Am Rev
Respir Dis 1992; 146: 1524–l530.
24. Campbell LM, Gooding TN, Aitchison WR, Smith N, Powell JA.
Initial loading (400mg twice daily) versus static (400mg nocte) dose
budesonide for asthma management. PLAN Research Group. Int J
Clin Pract 1998; 52: 361–370.
25. Chapman KR, Walker L, Cluley S, Fabbri L. Improving
patient compliance with asthma therapy. Respir Med 2000;
94: 2–9.
